Patients who have banked adipose tissue often ask a reasonable next question: does expanded access give a way to use it? This guide explains what expanded access actually is, what it is not, and why banking a person’s own tissue does not by itself open an expanded access pathway. The goal is a clear, honest picture so expectations match reality.
TLDR: Expanded access, sometimes called compassionate use, is a pathway for patients with serious or life-threatening conditions to seek an investigational product from its manufacturer after approved options are exhausted and when no clinical trial is available. It is physician-initiated, requires the manufacturer’s cooperation, and involves FDA and an institutional review board. Expanded access applies to a manufacturer’s investigational product, not to a patient’s own banked adipose tissue, so banking does not create an expanded access pathway. Banking preserves a person’s own tissue for potential future use; it does not guarantee eligibility, access, or any clinical benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease or condition. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
Expanded access is one of the most searched and least understood topics for patients exploring options beyond approved care. Understanding how it works, and how it relates to banking, helps a patient ask better questions and avoid false expectations.
What Expanded Access Is (and Is Not)
Expanded access is a pathway that may allow a patient with a serious or life-threatening condition to obtain an investigational product that is not yet FDA-approved, when the patient has exhausted approved options and is not eligible for a relevant clinical trial. It is also called compassionate use, named-patient use, or single-patient access. The key word is investigational, meaning a product a manufacturer is developing under FDA oversight.
It is equally important to understand what expanded access is not. It does not guarantee access to any therapy, it is not patient-initiated in the sense that a patient cannot simply demand a product, and it does not apply to a person’s own banked tissue. A treating physician submits the request, the manufacturer must agree to provide the product, and an institutional review board and the FDA are involved. The overview of expanded access programs describes the legal mechanics in more detail.
How Expanded Access Differs From a Clinical Trial
Expanded access and clinical trials are different routes, and the distinction matters. A clinical trial is a structured research study with eligibility criteria, protocols, and endpoints, designed to generate evidence about a product. Expanded access, by contrast, is a route for an individual patient to obtain an investigational product outside a trial, generally when no suitable trial is available.
For most patients, a clinical trial is the first avenue to consider, because trials are how investigational products are studied and how access is most commonly structured. The overview of clinical trials for regenerative medicine explains how studies are organized, and the current active clinical trials show what is enrolling. Expanded access is generally considered only after trial options have been ruled out.
Does Banking Your Tissue Connect You to Expanded Access?
This is the central question, and the honest answer is no. Expanded access applies to a manufacturer’s investigational product moving through FDA-regulated development, not to a patient’s own banked adipose tissue. Because banked tissue is the patient’s own preserved tissue rather than a manufacturer’s investigational product, there is no expanded access pathway that banking by itself creates.
Banking preserves optionality in a narrow sense: it stores a person’s own tissue so it exists if future FDA-regulated pathways, which may or may not develop, ever become relevant. It does not enroll a patient in anything, it does not create eligibility for expanded access or a trial, and it is not a treatment. Setting that expectation clearly is the most useful thing this article can do.
How the Reagan-Udall Navigator Works
For patients and physicians exploring expanded access, the Reagan-Udall Foundation for the FDA operates the Expanded Access Navigator at navigator.reaganudall.org. The Reagan-Udall Foundation is an independent nonprofit created by Congress to support the FDA’s mission, and the Navigator provides organized information about the single-patient expanded access process.
The Navigator helps a patient and physician determine whether an approved option, a clinical trial, an existing expanded access program, or a single-patient request is appropriate, and it maintains a directory of manufacturer expanded access policies. Practically, a request begins with a physician, requires the manufacturer’s authorization to provide the product, and involves FDA and an institutional review board. The Navigator is a guide to that process, not a guarantee that any product will be provided.
The Realistic Pathway for a Patient With Banked Tissue
A realistic pathway starts with disease-directed care and a conversation with the treating physician. If a patient is seeking options beyond approved care, the usual sequence is to consider whether a relevant clinical trial is enrolling, and only then to explore whether expanded access to a specific investigational product might be appropriate, with the physician leading any request.
Throughout, banked tissue sits to the side of these pathways rather than driving them, because expanded access and trials concern manufacturer investigational products. For background on the service itself, the complete guide explains what banking is and is not. The honest framing is that banking is a preservation decision, and any future use depends on FDA regulatory status and the science at that time.
What to Ask Your Physician About Future Pathways
A focused conversation with a physician produces better decisions than online research alone. A patient can ask whether any relevant clinical trials are enrolling, whether the physician considers expanded access appropriate for the patient’s situation, and what the realistic options are given the current state of approved and investigational care.
It also helps to ask the physician to explain why expanded access applies to manufacturer investigational products rather than to banked tissue, so the distinction is clear. A trustworthy physician will reinforce that banking preserves tissue for potential future use and creates no guarantee of access or benefit.
Frequently Asked Questions
Does banking my tissue give me access to expanded access programs?
No. Expanded access applies to a manufacturer’s investigational product, not to a patient’s own banked tissue. Banking does not create an expanded access pathway, and any future use depends on FDA regulatory status and the science at that time.
Can I request expanded access myself?
No. Expanded access is physician-initiated. A treating physician submits the request, the manufacturer must agree to provide the investigational product, and the FDA and an institutional review board are involved.
Is expanded access a guarantee of treatment?
No. It is a pathway that may allow access to an investigational product in specific circumstances, but it guarantees nothing. The manufacturer must agree, and the product remains investigational rather than approved.
What is the Reagan-Udall Navigator?
It is an online resource from the Reagan-Udall Foundation for the FDA, at navigator.reaganudall.org, that provides organized information to help patients and physicians understand the single-patient expanded access process and locate manufacturer policies.
Should I consider a clinical trial first?
Generally, a clinical trial is the first avenue to discuss with a physician, because trials are how investigational products are studied. Expanded access is usually considered only when no suitable trial is available.
Key Takeaways
For patients who have banked tissue, the most important point is that expanded access does not change what banking is. Expanded access is a physician-initiated pathway for patients with serious or life-threatening conditions to seek a manufacturer’s investigational product after approved options are exhausted and when no trial is available, and it requires the manufacturer’s cooperation along with FDA and institutional review board involvement. Because it applies to a manufacturer’s investigational product rather than to a patient’s own banked tissue, banking does not create an expanded access pathway. The Reagan-Udall Navigator can help a patient and physician understand the process, but it guarantees nothing. Above all, banking adipose tissue is a preservation service for potential future use; it is not a treatment, and it does not guarantee eligibility, access, or clinical benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Patients who want to understand what banking does and does not offer can review the complete guide and contact the team with questions.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review is required before publication. Please consult your physician before making any decisions about treatment or research participation.
Related guide: the physician resource center.
